Relationship of serum HER-2/neu and serum ca 15-3 in patients with metastatic breast cancer

Clinical Chemistry

Volumn 48, Issue 8, 2002, Pages 1314-1320

  Ali, Suhail M ^a   Leitzel, Kim ^a   Chinchilli, Vernon M ^a   Engle, Linda ^a   Demers, Laurence ^a   Harvey, Harold A ^a   Carney, Walter ^a   Allard, Jeffrey W ^a   Lipton, Allan ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FADROZOLE; MEGESTROL ACETATE; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC KIT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; RETROSPECTIVE STUDY; TUMOR VOLUME;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0036329461     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.8.1314     Document Type: Article

References (24)

1. Impact of selection process on response rate and long term survival of potential high dose chemotherapy candidates treated with standard-dose doxorubicin containing chemotherapy in patients with metastatic breast cancer
2. Prognostic significance of estrogen receptor levels in estrogen receptor positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study
3. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
4. Dose-response trial of megestrol acetate in advanced breast cancer: Cancer and leukemia group B phase III study
5. The neu (c-erbB-2) oncogene
6. Amplification of a novel v-erbB-2 related gene in a human mammary carcinoma
7. The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor
8. The role of erbB-2 signal transduction pathways in human breast cancer
9. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
10. Follow-up study of HER-2/neu amplification in primary breast cancer
11. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene
12. In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells
13. Detection and quantitation of the human neu oncoprotein
14. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients
15. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
16. HER-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
17. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
18. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis
19. Baseline serum HER2 (sHER2) levels in pivotal herceptin breast cancer trials: A comparison of 2 ELISA methods
20. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of HER-2/neu protein
21. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
22. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature of HER-2. p53, and BCL-2
23. Factors predicting for efficacy and safety of doxetaxel in a compassionate use cohort of 825 heavily pretreated advanced breast cancer patients
24. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen